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Heparin acts as a structural component of β-endorphin amyloid 
fibrils rather than a simple aggregation promoter  
N. Nespovitaya, P. Mahou, R. F. Laine, G. S. Kaminski Schierle, C. F. Kaminski* 
The aggregation promoter heparin is commonly used to study the 
aggregation kinetics and biophysical properties of protein 
amyloids. However, the underlying mechanism for amyloid 
promotion by heparin remains poorly understood. In the case of 
the neuropeptide β-endorphin that can reversibly adopt a 
functional amyloid form in nature, aggregation in the presence of 
heparin leads to a loss of function. Applying correlative optical 
super-resolution microscopy methods, we show that heparin 
incorporates into emerging β-endorphin fibrils forming an integral 
component and is essential for amyloid templating. This will have 
direct implications on β-endorphin’s normal physiological function 
and raises concerns on the biological relevance of heparin-
promoted amyloid models. 
The endogenous opiate β-endorphin is an essential 
neuropeptide involved in the stress response of higher 
organisms 1. In the secretory pathway, it is temporarily stored 
in dense-core vesicles in the amyloid form, which 
disaggregates upon vesicle secretion into the blood 2,3. The 
reversibility of aggregation of β-endorphin and some other 
neuropeptides renders them fundamentally different from 
most functional amyloids, and probably all disease-related 
amyloids, which aggregate irreversibly 2–5. 
Previous work on β-endorphin aggregation investigated 
structure-activity relationships of amyloids induced by high- 
and low-molecular-weight aggregation promoters, including 
heparin and salts of polyprotic acids. 3  
Heparin is one of the most commonly used promoters of 
aggregation. However, its mechanism of action is a subject of 
considerable debate 6. Studies with transmission electron 
microscopy (TEM), fluorescence and NMR spectroscopy 
revealed morphological and structural differences between 
β-endorphin aggregates induced with heparin, and those that 
were not (see Fig. 1). Moreover, heparin-promoted amyloids 
demonstrated an increased stability in dissociation assays. 3 
These dramatic changes in fibril structure and function raise 
fundamental questions on the role of heparin in protein 
aggregation. 
Our working hypothesis in the present study is that heparin is 
not simply a molecular crowding agent, as suggested in recent 
models 7,8, but instead that it co-aggregates with the peptide 
into a composite amyloid, at least in the case of β-endorphin. 
This, in turn, leads to a change of the biophysical, dynamic 
structural properties of the β-endorphin amyloid and its 
morphology. We thus predicted for heparin to be associated 
with the peptide along the whole fibril axis and tested this 
hypothesis with two-colour optical super-resolution 
microscopy (SRM) 9. In combination with differential labelling, 
SRM permitted an unambiguous identification of the labelled 
compounds and their relative arrangement at a nanometric 
scale 9–11. Importantly, alternative high-resolution methods of 
structural biology, such as NMR spectroscopy and X-ray 
crystallography, cannot address the question of peptide-
heparin colocalisation, due to the structural heterogeneity of 
natural heparin 12. Alternative high-resolution microscopy 
method such as TEM used in combination with immunogold 
labelling overcomes that latter disadvantage, however, has 
comparatively low resolution because of the large sizes of gold 
particles and linker lengths 13.  The technique is also hampered 
by the sparse labelling density usually achieved. Moreover, it 
does not permit the reliable differentiation of de novo fibril 
growth from the original seed species. 
Using two-colour direct stochastic optical reconstruction 
microscopy (dSTORM) 14 we made two key findings: 1) heparin 
co-aggregates with β-endorphin and becomes a structural 
element of the amyloid, and 2) heparin-promoted fibrils are 
not capable of templating the amyloid growth in the absence 
of heparin. 
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Fig. 1. Comparative visualisation of β-endorphin amyloid fibrils obtained in the 
presence (a, c) and absence of heparin (b, d). TEM (a, b) and AFM (c, d) images 
show heparin-promoted fibrils as long individual filaments, while β-endorphin 
amyloids formed in heparin-free aggregation buffer are short and form bundles. 
In all case, fibrils were obtained at 60 µM peptide concentration (a-d) and 20 µM 
heparin (a, c). In all cases, aggregation buffer was composed of 50 mM sodium 
phosphate and 2 mM sodium citrate at pH 6.0. Scale bars are 1 µm. 
In order to test our hypothesis of colocalisation of β-endorphin 
and heparin within the fibrils, we obtained β-endorphin 
amyloids by co-incubation of the peptide labelled with 
AlexaFluor 568 dye (AF568) and heparin conjugated with 
AlexaFluor 647 (AF647) and imaged them with two-colour 
dSTORM. The fibrillar nature of the obtained sample was 
confirmed by atomic force microscopy (AFM, Fig. 2a). Further, 
350 fibrils identified in 35 random fields of view showed 
colocalisation of fluorescent signals in both the peptide and 
heparin imaging channels (exemplified in Fig. 2b-d). A pixel-
based analysis of β-endorphin and heparin colocalisation 
within the amyloid fibrils further supports this visual 
observation (Suppl. Fig. S1). To ensure that fluorescence 
images were good representations of β-endorphin fibrils, we 
used stimulated emission depletion (STED) 15 microscopy 
correlated with AFM. β-endorphin fibrils labelled with AF647 
attached to either the peptide (Figures 2e-f) or to heparin 
(Figures 2g-h) were imaged with STED and then with AFM. All 
structures observed by AFM had fibrillar shapes and exhibited 
the fluorescence signal everywhere along the fibril axis, 
confirming that all optical images were adequate 
representations of β-endorphin fibrils and that heparin was 
evenly distributed along the fibrils. The data obtained here by 
two independent SRM techniques provide unequivocal 
evidence of the tight association of heparin with the  
β-endorphin amyloid fibrils. Next, we tested whether heparin 
becomes an integral component of β-endorphin fibrils or 
associates unspecifically with the amyloid. We performed an 
elongation assay where fibrillar seeds of β-endorphin amyloids 
were incubated with the monomeric peptide under various 
conditions (see Fig. 3 cartoons). Two-colour dSTORM 
demonstrated that heparin-promoted β-endorphin amyloids 
grow by incorporation of both the peptide and heparin into 
the fibril termini (Figures 3b-d). At the same time, heparin- 
promoted fibril seeds incubated with monomeric β-endorphin 
in the heparin-free environment did not elongate axially and 
appeared as short two-colour fibrils (Figures 3e-f, Suppl. Fig. 
S2), 
 
Fig. 2. β-endorphin and heparin are associated within amyloid fibrils. The fibrillar nature of heparin-promoted β-endorphin aggregates labelled with two fluorophores 
was confirmed by AFM (a). The fibrils were obtained at 60 µM total peptide concentration including 10 % (mol.) of the AF568-labelled peptide (b, green) and 20 µM 
heparin labelled with AF647 (c, magenta). Colocalisation is displayed in (d, white), where super-resolved images from (b, green) and (c, magenta) are merged. Further, 
β-endorphin fibrils containing AF647 fluorophore attached either to the peptide (e, f) or to heparin (g, h) were examined by co rrelated STED/AFM microscopy. A field 
of view was first acquired via STED (e, g) and subsequently probed by AFM (f, h). Optical images are seemed to fully reflect the fibrillar morphology of β -endorphin 
amyloids with either labelling scheme. Scale bars are 1 µm in a-d and 2 µm in e-h. 
Journal Name  COMMUNICATION 
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 3  
Please do not adjust margins 
Please do not adjust margins 
Fig 3. Elongation of heparin-promoted β-endorphin seeds in the presence and absence of heparin. (a) Visual legend to the cartoons illustrating the experimental 
conditions for each column of data. The chevron and line symbols represent β-endorphin and heparin molecules, respectively. The colours reflect labelling scheme for 
β-endorphin and heparin: grey – unlabelled, green – labelled with AF568, magenta – labelled with AF647. Panels below the cartoon display representative dSTORM 
images of the resulting aggregates. The seeds were obtained at 60 µM total peptide concentration including 10 % (mol.) of labelled β-endorphin and 20 µM heparin. 
In (b, c, e), seeds formed by AF568-labelled peptide and unlabelled heparin were used for elongation at three different conditions. In (b) AF647-labelled β-endorphin 
was added to fibril seeds together with unlabelled heparin. Alternatively, unlabelled β-endorphin was added to the seeds together with AF647-labelled heparin in (c). 
In (e) AF568-labelled seeds were transferred to the solution containing AF647-labelled β-endorphin with no heparin. In conditions (d, f), β-endorphin seeds were 
formed by the unlabelled peptide and AF647-labelled heparin. Further, these seeds were mixed with AF568-labelled peptide either in the presence (d) or in the 
absence of heparin (f). Scale bars are 500 nm. 
which suggests lateral adhesion of the added monomer on the 
seed surface. This notion is supported by a comparative AFM 
analysis of fibril height before and after the elongation assay, 
which indeed revealed that the seeds thicken upon the 
addition of the monomeric peptide (Supplementary Fig. S3). 
Notably, β-endorphin amyloids elongated in the presence of 
heparin retained twisted fibrillar morphology similar to 
parental heparin-promoted seeds (Suppl. Fig. S4). 
In summary, our experiments demonstrate the coaggregation 
of heparin and β-endorphin into composite amyloid fibrils. The 
data obtained via two-colour dSTORM explain previously 
reported striking differences between the properties of 
heparin-promoted and heparin-free β-endorphin amyloids 3. 
The association of heparin with the peptide leads to a 
fundamentally different fibril structure that renders the 
aggregation process irreversible, and, hence, leads to a loss of 
function of β-endorphin amyloids 3, which in nature is required 
to reversibly interchange between aggregated and monomeric 
states. Our findings have significant implications for the 
interpretation of structure-activity relationships and raise 
concerns on the biological relevance of heparin-promoted 
amyloid models. The latter is especially relevant for 
β-endorphin and other functional hormone amyloids since the 
concentration of heparin in the secretory pathway is 
insignificant 12. Given the widespread adoption of heparin as a 
universal aggregation promoter 2,16–20, the presented findings 
are quite generally relevant to the field of amyloid research. 
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